Triplebar’s core product is its Hyper‑Throughput™ screening platform, described as a “microprocessor for biology” that integrates hardware, software, biology and biochemistry to miniaturize and accelerate evolution. The platform is used to develop biological systems for low-cost, low-footprint animal proteins, improve performance of animal cell lines for cellular meat, and discover novel therapeutic biologic candidates. Triplebar positions itself as a multi-product, multi-vertical product design engine serving food, nutrition and healthcare verticals, including bioactives, functional food proteins, cultured meat, and novel biologics. The company works with commercial partners and corporate collaborators to scale manufacturing via fermentation and cell-line optimization without genetic modification. Recent partnerships include collaboration with Umami Bioworks on cultivated seafood cell lines and with FrieslandCampina to co-develop scalable nutritional ingredients. Triplebar announced $20M in new funding to expand its product portfolio across food and biopharmaceuticals.

Total raised

$20M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2023